Lisa Goerens's research while affiliated with Universität des Saarlandes and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (4)
Recently, neurabin-I and SAMD14 have been described as the autoantigenic target of approximately 66% of B-cell receptors (BCRs) of primary central nervous system lymphomas (PCNSL). Neurabin-I and SAMD14 share a highly homologous SAM domain that becomes immunogenic after atypical hyper-N-glycosylation (SAMD14 at ASN339 and neurabin-I at ASN1277). Th...
Chronic antigenic stimulation of the B-cell receptor (BCR) seems to play a critical role in the pathogenesis of B-cell lymphomas. We recently identified ARS2, LRPAP1 and Neurabin-I as the autoantigenic targets of the B-cell receptors of approximately 25% of diffuse large B cell lymphomas (DLBCLs) of the ABC type, 45% of mantle cell lymphomas (MCLs)...
Background
Chronic antigenic stimulation of the B-cell receptor (BCR) seems to play a critical role in the pathogenesis of B-cell lymphomas. We recently identified ARS2 and LRPAP1 as the autoantigenic targets of the B-cell receptors of approximately 25% of diffuse large B cell lymphomas (DLBCLs) of the ABC type and 45% of mantle cell lymphomas (MCL...
Citations
... Antigenic BCR stimulation by autoantigens has been proposed as pivotal pathway for malignancy in several types of lymphoma. We have identified and characterized several autoantigens as the specific targets of BCRs or the paraprotein of different B-cell malignancies [9][10][11][12][13][14][15][16]. Ars2 was reported as the autoantigenic target of the BCR in approximately 25% of all ABC-type DLBCL cases [17] The BCR of lymphoma cells represents an ideal target for new therapeutic approaches and different BCR-targeting therapeutic formats like anti-idiotype antibodies and peptibodies have been developed with moderate clinical success [18][19][20][21][22][23]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/662874095624192-1535052908837_Q64/Moritz-Bewarder.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1048641376645125-1627026995860_Q64/Maximilian-Kiefer-2.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1147391273123841-1650570805165_Q64/Lorenz-Thurner.jpg)
... Bewarder et al. applied the B-cell receptor Antigen for Reverse targeting (BAR) approach to develop a molecule that resembles an IgG1 antibody and contains the BCR-binding epitope of the common CNS-DLBCL antigens SAMD14 and neurabin-I instead of variable regions to target the B-cell receptors with specificity for neurabin-I (198). The IgG1format neurabin-I BAR-body shows in vitro ability to induce antibody-dependent cell-mediated cytotoxicity and, based on in vivo data obtained with a similar molecule, it might represent a future therapeutic approach (199), although its efficacy and safety still require extensive validations (200). ...
